Mylan Institutional LLC v. Aurobindo Pharma Ltd.

E-Law Admin/ Mai 19, 2017/ Arzneimittelrecht Schweiz/ 0Kommentare

Mylan Institutional LLC v. Aurobindo Pharma Ltd., 2017-1645

In an infringement action involving patents which relate to isosulfan blue (ISB), a triarylmethane dye used to map lymph nodes, the district court’s grant of plaintiff’s motion for a preliminary injunction precluding defendant from making, using, selling, offering to sell, and importing the accused ISB product is affirmed where, although it did err in granting the injunction under the ‘992 and ‘616 patents, the district court did not err in its grant of the preliminary injunction under the ‘050 patent.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2017/05/19

Judges

Court

  • United States Federal Circuit

Counsel


e-Law Trainer

Share this Post

Hinterlasse einen Kommentar